Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;26(9):4078-4086.
doi: 10.1111/dom.15766. Epub 2024 Jul 15.

Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment

Alessandro Rizzi  1 , Linda Tartaglione  1 , Lorenzo Lucaccini Paoli  1 , Maria Laura Leo  1 , Valentina Popolla  1 , Luca Viti  1 , Annarita Barberio  1 , Mauro Di Leo  1 , Alfredo Pontecorvi  2 , Dario Pitocco  1
Affiliations

Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment

Alessandro Rizzi et al. Diabetes Obes Metab. 2024 Sep.

Abstract

Aim: To assess the long-term glycaemic outcomes, with additional metrics, in adults with type 1 diabetes (T1D) using the Tandem t:slim X2 with Control-IQ technology advanced hybrid closed-loop (AHCL) system.

Methods: This was a single-centre, retrospective study involving 56 T1D patients who transitioned to the Tandem t:slim X2 with Control-IQ system. The primary and secondary endpoints consisted of variations in time in tight range (TiTR; 70-140 mg/dL) and the glycaemia risk index (GRI), respectively. Additional standardized continuous glucose monitoring (CGM) metrics, mean sensor glucose, coefficient of variation, the glucose management indicator (GMI), HbA1c and insulin daily dose, were also evaluated. Variables were measured at baseline and at 15 days, 3 months, 6 months and 1 year after Tandem t:slim X2 Control-IQ initiation. Glucose outcomes are expressed as mean (standard deviation).

Results: Use of Tandem t:slim X2 with Control-IQ over 1 year was associated with an increase in mean TiTR, from 38.11% (17.05%) to 43.10% (13.20%) (P = .059), and with a decline in the GRI, from 41.03 (25.48) to 28.55 (16.27) (P = .008). CGM metrics, including time in range and time above range, showed consistent improvements. Mean sensor glucose, the GMI and HbA1c decreased significantly over time. After an initial increase, insulin daily dose remained stable throughout the 12 months.

Conclusions: The results highlight the sustained effectiveness of Tandem t:slim X2 with Control-IQ in improving glycaemic outcomes over 1 year and support the use of this technology for the management of T1D.

Keywords: continuous glucose monitoring; glycaemia risk index; hyperglycaemia; time in tight range; type 1 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593‐1603. doi:10.2337/dci19‐0028
    1. Tauschmann M, Hovorka R. Technology in the management of type 1 diabetes mellitus—current status and future prospects. Nat Rev Endocrinol. 2018;14(8):464‐475. doi:10.1038/s41574‐018‐0044‐y
    1. Galindo RJ, Aleppo G. Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology. Diabetes Res Clin Pract. 2020;170:108502. doi:10.1016/j.diabres.2020.108502
    1. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631‐1640. doi:10.2337/dc17‐1600
    1. American Diabetes Association. Standards of medical Care in Diabetes—2022 abridged for primary care providers. Clin Diabetes. 2022;40(1):10‐38. doi:10.2337/cd22‐as01

MeSH terms